Thomas Jefferson University

Jefferson Digital Commons
Department of Cancer Biology Faculty Papers

Department of Cancer Biology

4-10-2017

Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell
Cycle.
Matthew J. Schiewer
Thomas Jefferson University

Karen E. Knudsen
Thomas Jefferson University

Follow this and additional works at: https://jdc.jefferson.edu/cbfp
Part of the Oncology Commons

Let us know how access to this document benefits you
Recommended Citation
Schiewer, Matthew J. and Knudsen, Karen E., "Not So Fast: Cultivating miRs as Kinks in the
Chain of the Cell Cycle." (2017). Department of Cancer Biology Faculty Papers. Paper 132.
https://jdc.jefferson.edu/cbfp/132
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Cancer Biology Faculty Papers by an authorized administrator of the
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

HHS Public Access
Author manuscript
Author Manuscript

Cancer Cell. Author manuscript; available in PMC 2018 April 10.
Published in final edited form as:
Cancer Cell. 2017 April 10; 31(4): 471–473. doi:10.1016/j.ccell.2017.03.012.

Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell
Cycle
Matthew J. Schiewer1,5 and Karen E. Knudsen1,2,3,4,5,*

Author Manuscript

1Department

of Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA

2Department

of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA

3Department

of Urology, Thomas Jefferson University, Philadelphia, PA 19107, USA

4Department

of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA

5The

Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA

Abstract
In this issue of Cancer Cell, Hydbring and colleagues define a novel class of microRNAs
(miRNAs), deemed “cell-cycle-targeting miRNAs,” that target several cyclins/CDKs, reduce
tumor cell growth, and induce apoptosis. These miRNAs effectively suppressed chemoresistant
patient-derived xenograft growth in vivo, and efficacy could be prospectively predicted with an
expression-based algorithm.
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One of the hallmarks of cancer is unbridled cell proliferation, often manifesting through
alterations of the cell-cycle machinery, including cyclin-dependent kinases (CDKs) and their
cognate catalytic partners, the cyclins (Hanahan and Weinberg, 2011). Cyclin/CDK
complexes regulate cell-cycle phase transitions through selective phosphorylation of
substrates that control all aspects of cell division, including commitment to completion of a
mitotic cell cycle, achieved through phosphorylation and inactivation of the retinoblastoma
(RB) tumor suppressor protein. These functions are counterbalanced by canonical
endogenous CDK inhibitors and tumor suppressors. Loss of these cell-cycle-attenuating
tumor suppressors, or, by contrast, deregulation of cyclins, CDKs, or CDK targets, can
afford a mechanism for tumor cells to bypass the appropriate cell-cycle regulation and occur
at high frequency in human malignancies (Otto and Sicinski, 2017). As such, developing
effective therapeutic means to thwart cell-cycle dysregulation may lead to significant benefit
for cancer patients.
The study by Hydbring et al. brings understanding to the role of miRNAs in controlling cellcycle regulatory proteins and supports the concept that miRNA function could be harnessed
as a means to counteract unchecked cell-cycle progression (summarized in Figure 1)
(Hydbring et al., 2017). miRNAs are short, regulatory RNA species that reduce the
expression of gene products by inducing mRNA degradation or inhibition of translation
(Lagos-Quintana et al., 2001). Similar to the cell-cycle machinery, miRNAs show frequent

*

Correspondence: karen.knudsen@jefferson.edu.

Schiewer and Knudsen

Page 2

Author Manuscript

alteration in human malignancy (Lu et al., 2005). Understanding of miRNA function is a
fertile ground of current investigation, and a number of potential applications in both
diagnostics and therapeutics have been realized (Adams et al., 2017; Hydbring and
Badalian-Very, 2013). Hydbring et al. screened for miRNAs that target nine cyclins and
CDKs of importance for cell division in cancer cells. The results of this screen revealed 30
miRNAs with the capacity to target five or more cyclins/CDKs and 14 miRNAs capable of
targeting six or more cyclins/CDKs, thus demonstrating a novel class of miRNAs that
regulate nearly all components of the cell-cycle machinery. The number of miRNAs that
target multiple cyclins/CDKs is significantly higher than predicted by chance alone.
Furthermore, prioritization studies identified anti-correlation of selected miRNAs with
anticipated cyclin/CDKs in human tumors, and the miRNAs were found to be
downregulated or deleted in several tumor types.
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Building upon these initial findings, a second screen utilizing a 122-cancer-cell-line library
comprised of 12 tumor types was employed to test the efficacy of these cell-cycle-targeting
miRNAs. Four miRNAs identified in the initial screen demonstrated significant growthinhibitory effects in the cell lines examined, albeit to differing magnitudes. Strikingly, cells
derived from gastric cancers and triple-negative breast cancers (TNBCs) demonstrated a
more robust response, potentially due to greater reliance on the targeted cyclins/CDKs. In
these tissue types, it was further noted that cell-cycle-targeting miRNAs harbored the
capacity to induce apoptosis, suggesting that the miRNAs elicit not only the expected
cytostatic effects but also cytotoxic responses. Investigation of the underlying basis for
enhanced responsiveness in TNBC and gastric cancer may therefore lay the foundation for
determining which tumors may be most responsive to miR-based therapies targeting cellcycle regulation.
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Recent clinical successes targeting CDK activity have increased enthusiasm for refining the
means to suppress cell-cycle control in a subset of tumor types, most particularly as related
to CDK4/6 inhibitors (CDK4/6i). The CDK4/6i palbociclib is FDA approved for the
treatment of estrogen receptor (ER)-positive, HER2-negative advanced breast cancer in
combination with estrogen deprivation or ER-targeted therapies (letrozole or fulvestrant,
respectively) (Finn et al., 2015; Turner et al., 2015), based in part on clinical trial data
demonstrating that the combination resulted in improved progression-free survival (PFS)
compared to hormone therapy alone. More recently, the CDK4/6i ribociclib was FDA
approved for this same patient population in combination with letrozole, based on clinical
data indicating that the combination lengthened PFS (Hortobagyi et al., 2016). In principle,
the studies here have the potential to build on the success of CDK4/6i, as the miRNAs
identified proved capable of simultaneously suppressing more than five to six CDKs or
cyclins and therefore could provide a more potent mechanism to suppress the cancer cell
cycle. Furthermore, whereas CDK4/6i are approved for ER-positive disease, the data from
Hydbring et al. identified ER-negative tumor models (TNBC) as exceptional responders to
miRNA-based cell-cycle suppression. Head-to-head comparison revealed that miR193a-3p
is more effective than palbociclib in blocking TNBC cell growth, and miR193a-3p elicits
anti-tumor effects even in the context of RB loss, which renders cells resistant to palbociclib.
miR193a-3p was also more effective than lapatinib in HER2-positive cells and was
comparable to the combination of lapatinib and palbociclib. While these findings require
Cancer Cell. Author manuscript; available in PMC 2018 April 10.
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validation and development of translational potential, the study by Hydbring et al. provides
robust evidence that cell-cycle-targeting miRNAs hold promise as anti-cancer agents that
may hold advantages over CDK4/6 targeting alone in breast cancer.
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Harnessing the miRNAs for translational potential yielded promising results in patientderived xenograft (PDX) models of chemotherapy-resistant TNBC and colorectal cancer. In
both systems, miRNA-containing nanoparticles were effective in eliciting anti-tumor
responses, whereas normal tissues were spared any toxicity. In a doxorubicin- and taxaneresistant TNBC PDX, nanoparticles containing miR193a-3p reduced proliferation and
induced apoptosis, demonstrating that cell-cycle-targeting miRNA therapy may be effective
in chemotherapy-resistant tumors. Furthermore, in a KRAS mutant FOLFOX- and
FOLFIRI-resistant colorectal tumor PDX, miR214-5p blocked tumor growth while sparing
normal tissues and was more effective in KRAS mutant than wild-type cells. These data
indicate that tumor phenotype and/or genotype may influence the utility of cell-cycletargeting miRNAs. Given the demonstrated selectivity, it is intriguing to speculate that the
heightened reliance of tumor cells on cyclins/CDKs can be effectively targeted in malignant
tissues using the cell-cycle-targeting miRNA strategy.
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Hydbring et al. also developed an expression-based algorithm to predict responses to cellcycle-targeting miRNAs. As proof of principle, the authors transcriptionally profiled an
aggressive dermatofibrosarcoma protuberans that was resistant to both Gleevec and PI3K
inhibition. Utilizing the developed algorithm, it was predicted that the tumor would be
responsive to miR-193a-3p. Subsequent administration of nanoparticles containing
miR193a-3p to mice harboring a PDX of the dermatofibrosarcoma protuberans resulted in
significant reduction of tumor growth, demonstrating the utility of the algorithm. Based on
these exciting findings, future studies examining combinatorial strategies with cell-cycletargeting miRNAs may lead to effective means of managing malignancy.
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There are currently three clinical trials utilizing miRNA-based therapies listed on
www.clinicaltrials.gov. Two (NCT01829971, NCT02862145) were recently terminated due
to immune-related serious adverse events, suggesting that a proper nomination schema, as
might be done with the expression-based algorithm described by the authors, may be needed
to optimize miRNA-based therapies. The third therapeutic miRNA trial is a phase I trial
utilizing a miR-16 mimic in progressive mesothelioma and non-small-cell lung cancer
(NCT02369198), which is employing an epidermal growth factor receptor-targeting
mechanism. A targeting strategy may be needed to circumvent the possible toxicity of
miRNA-based cancer therapy, although the work by Hydbring et al. demonstrates that use of
nanoparticles to deliver cell-cycle-targeting miRNAs does not elicit toxicity in
immunocompromised mice. Importantly, while several studies that have examined the
capacity of miRNA-based technology to be clinically useful report mixed results, the
strategy defined by the authors provides hope for using cell-cycle-targeting miRNAs for
cancer management in the near future.
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Figure 1. Summary of Hydbring et al

Through several screens, it was determined that a subset of miRNAs target cyclins and
CDKs, which are positive drivers of the cell cycle. These “cell-cycle-targeting miRNAs”
were found to be inversely correlated with cyclins/CDKs in The Cancer Genome Atlas
(TCGA) data, as well as either reduced or deleted in several tumor types. Therapeutic
efficacy of these cell-cycle-targeting miRNAs was enriched in TNBC and gastric cancer cell
lines, which was validated in chemotherapy-resistant PDX models.
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